CMTA is leading a coordinated CMT1A research strategy that connects disease models, drug development, biomarkers, delivery science, and clinical infrastructure to accelerate new treatments.
CMTA Expands Preclinical Toolbox with New CMT1A Assay
CMTA expands its Preclinical Toolbox with a new CMT1A assay, providing researchers with a human-relevant platform to evaluate potential therapies earlier in drug development.
CMT2A in the Lab: A Closer Look at How Treatments Are Tested
What if you could watch CMT2A unfold inside a neuron? CMTA’s new partnership just made it possible, and the early findings are changing the game.
Human Myelin Organoid as a Reference Model for CMT1A
Researchers led by CMTA-STAR Advisory Board member Vincent Timmerman, PhD, at the University of Antwerp are developing human-derived CMT1A organoids using patient-derived stem cells. This research platform aims to improve understanding of disease mechanisms and provide a standardized model for evaluating potential treatments.
CMTA Invests Over $200K in CMT1A Organoid Research
CMTA announced an investment of more than $200,000 to support CMT1A organoid research, establishing standardized models to evaluate therapies targeting CMT1A.
A New CMT1A Research Toolbox Using Human Stem Cells
With CMTA support of $98,890, researchers at Hasselt University in Belgium, led by Esther Wolfs,...
